Biohaven Ltd. (BHVN) Stock Price

BHVNStock
$15.410.71%52W
Market Cap$2.33B
P/E
PEG Ratio
Div yield
Beta3.10

BHVN Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)18.00%
Price vs S&P 500 (4W)13.72%
VGM Score75.67

BHVN Earnings Surprise History

QuarterReport dateEPS estimateEPS actualSurprise
Q2 2026-$0.61-$0.78-27.61%(-$0.17)
Q1 2026-$0.76-$0.69+9.68%(+$0.07)
Q4 2025-$0.96-$0.90+5.77%(+$0.06)
Q3 2025-$1.93-$1.64+14.94%(+$0.29)
Q2 2025-$1.57-$1.63-3.96%(-$0.06)

BHVN Analyst Recommendations

May 2026
Jun 2026
Jul 2026
Aug 2026
4.04
4.04
4.00
4.04

Industry Peers — Pharmaceuticals(570)

SymbolValue ScoreGrowth ScoreMomentum ScorePrice
BHVNBiohaven Ltd.
B$15.41
LLYEli Lilly & Co.DBC$1174.61
JNJJohnson & JohnsonDCB$268.04
ABBVABBVIE INC.DCB$255.48
MRKMerck & Co., Inc.DCB$148.35
NVSNovartis AGCCC$153.81
AZNAstraZeneca PLCCBC$162.70
NVONovo-Nordisk A/SBCC$45.61
ABTAbbott LaboratoriesCCC$112.47
PFEPfizer Inc.CDB$27.96
VRTXVertex Pharmaceuticals IncDCB$541.69

About Biohaven Ltd.

Biohaven is a clinical-stage biopharmaceutical company developing treatments across immunology, neuroscience, and oncology. Its pipeline targets neuromuscular diseases, metabolic disorders, obsessive-compulsive disorder, and cancer, utilizing multiple therapeutic modalities including glutamate modulators, myostatin inhibitors, ion channel modulators, and antibody-drug conjugates. The company has multiple product candidates spanning these therapeutic areas at various development stages.